FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Matthews Andrea			2. Issuer Name and Ticker or Trading Symbol Astria Therapeutics, Inc. [ATXS]				(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (spe								
(Last)	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/08/2024					X	X Officer (give title below) Other below) Chief Business Officer				еспу	
C/O ASTRIA THERAPEUTICS, INC.				<u> </u>												
75 STATE STREET, SUITE 1400			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street)											X	_	•		•	
BOSTO	N M	ÍΑ	02109								Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication											
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							satisfy				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction ate lonth/Day/	Execution Date		Code (Instr.				5. Amoun Securities Beneficia Owned Fo	s F lly (6. Owner Form: Di (D) or Ind (I) (Instr.	irect In direct B 4) O	7. Nature of ndirect Beneficial Ownership		
							Code V	Amount	(A) o (D)	r Price	Transaction (Instr. 3 a			(11)	nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Code (ransaction Derivative ode (Instr. Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(5)		
Stock Option (Right to Buy)	\$15.26	02/08/2024		A		175,000		(1)	02/07/2034	Common Stock	175,000	\$0	175,000)	D	

Explanation of Responses:

1. This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 175,000 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments.

/s/ Noah Clauser, as attorney-in-02/12/2024 fact for Andrea Matthews

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.